ecNumber*3.4.22.34#specificActivity*-999#specificActivityMaximum*#commentary*#organism*Vigna radiata#literature*30308#!ecNumber*3.4.22.34#specificActivity*-999#specificActivityMaximum*#commentary*#organism*Phaseolus vulgaris#literature*30309#!ecNumber*3.4.22.34#specificActivity*-999#specificActivityMaximum*#commentary*#organism*Canavalia ensiformis#literature*30310#!ecNumber*3.4.22.34#specificActivity*-999#specificActivityMaximum*#commentary*#organism*Canavalia ensiformis#literature*30311#!ecNumber*3.4.22.34#specificActivity*-999#specificActivityMaximum*#commentary*#organism*Vigna aconitifolia#literature*30313#!ecNumber*3.4.22.34#specificActivity*-999#specificActivityMaximum*#commentary*#organism*Glycine max#literature*30314#!ecNumber*3.4.22.34#specificActivity*-999#specificActivityMaximum*#commentary*#organism*Homo sapiens#literature*651251#!ecNumber*3.4.22.34#specificActivity*-999#specificActivityMaximum*#commentary*#organism*Schistosoma mansoni#literature*668776#!ecNumber*3.4.22.34#specificActivity*-999#specificActivityMaximum*#commentary*ability of carboxy-terminal extensions and mutants of phytocystatin to inhibit in vitro human legumain shown, inhibitory activity measured by the inhibition of legumain proteinase activity, assay described#organism*Homo sapiens#literature*679859#!ecNumber*3.4.22.34#specificActivity*-999#specificActivityMaximum*#commentary*ability of carboxy-terminal extensions and mutants of phytocystatin to inhibit endogenous legumain activity present in barley protein extracts analyzed, inhibitory activity measured by the inhibition of legumain proteinase activity, assay described#organism*Hordeum vulgare#literature*679859#!ecNumber*3.4.22.34#specificActivity*-999#specificActivityMaximum*#commentary*expression in atherosclerotic tissues determined by RT-PCR, in situ hybridization and immunohistochemical analysis, role of legumain in the pathophysiology of atherosclerosis analyzed; expression in atherosclerotic tissues determined by RT-PCR, in situ hybridization and immunohistochemical analysis, role of legumain in the pathophysiology of atherosclerosis analyzed, human monocyte legumain activity assay described, migration/proliferation and invasion assay described; role of legumain in the pathophysiology of atherosclerosis analyzed, human monocyte legumain activity assay described, migration/proliferation and invasion assay described#organism*Homo sapiens#literature*683113#!ecNumber*3.4.22.34#specificActivity*-999#specificActivityMaximum*#commentary*expression determined by RT-PCR, in situ hybridization and immunohistochemical analysis, role of legumain in the pathophysiology of atherosclerosis analyzed; expression in atherosclerotic tissues determined by RT-PCR, in situ hybridization and immunohistochemical analysis, role of legumain in the pathophysiology of atherosclerosis analyzed#organism*Mus musculus#literature*683113#!ecNumber*3.4.22.34#specificActivity*-999#specificActivityMaximum*#commentary*positional scanning combinatorial library of peptide acyloxymethyl ketones (AOMKs) to probe subsite specificity of legumain, design of fluorescent activity-based probes indicating high selectivity and cell-permeability for monitoring legumain activity in complex proteome structures, selectivity of optimized legumain probes in intact cells shown, structure of developed probes indicated#organism*Homo sapiens#literature*683246#!ecNumber*3.4.22.34#specificActivity*-999#specificActivityMaximum*#commentary*assay of legumain activity described, fibronectin degradation by legumain shown, enhanced fibronectin processing by overexpression of legumain indicated, experimental design of unilateral ureteral obstruction reveals increased protein accumulation of fibronectin in the renal interstitial area in kidneys from legumain-deficient mice#organism*Mus musculus#literature*683472#!ecNumber*3.4.22.34#specificActivity*-999#specificActivityMaximum*#commentary*cleavage sites for N- and C-terminus indicated, predicted motif for vacuolar proteins analyzed, targeting ability sucessfully tested in Saccharum officinarum and in other plant species by transient expression analysis after biolistic bombardment using the construct pCvsEndoexp1#organism*Saccharum officinarum#literature*683495#!ecNumber*3.4.22.34#specificActivity*-999#specificActivityMaximum*#commentary*activity profile shown, specificity profile using a positional scanning synthetic combinatorial library indicated#organism*Ixodes ricinus#literature*683572#!ecNumber*3.4.22.34#specificActivity*-999#specificActivityMaximum*#commentary*involvement of legumain in backbone cyclization of plant-produced cyclotides determined, transient expression of precursor of the cyclotide kalata B1 in tobacco leads to production of the circular cyclotide, in vivo asparaginyl bond hydrolysis shown to be necessary for cyclization, reduced amounts of cyclic cyclotide shown by suppression of legumain either by decreasing gene expression or by a specific inhibitor, detection and quantification of cyclotide proteins by MALDI-TOF#organism*Nicotiana benthamiana#literature*683654#!ecNumber*3.4.22.34#specificActivity*-999#specificActivityMaximum*#commentary*involvement of legumain in backbone cyclization of plant-produced cyclotides analyzed, assay for asparaginyl bond hydrolysis in leaf extracts described#organism*Oldenlandia affinis#literature*683654#!ecNumber*3.4.22.34#specificActivity*-999#specificActivityMaximum*#commentary*involvement of legumain in backbone cyclization of plant-produced cyclotides analyzed, assay for asparaginyl bond hydrolysis in leaf extracts described#organism*Viola tricolor#literature*683654#!ecNumber*3.4.22.34#specificActivity*-999#specificActivityMaximum*#commentary*activity profile shown in crude worm protein extracts but not in excretion-secretion products of adult parasites, inhibition assay described, exon boundaries, landmark residues/motifs, and target areas for N- and C-terminal processing indicated; activity profile shown in crude worm protein extracts but not in excretion-secretion products of adult parasites, inhibition assay, exon boundaries, landmark residues/motifs, and target areas for N- and C-terminal processing#organism*Fasciola gigantica#literature*683856#!ecNumber*3.4.22.34#specificActivity*-999#specificActivityMaximum*#commentary*expression of the SmAE gene in adult Schistosoma mansoni suppressed by RNA interference, full processing and activity of cathepsin B1 in the absence of detectable SmAE protein observed, experimental data indicate that schistosome legumain is not essential to activate cathepsin B1 in vivo#organism*Schistosoma mansoni#literature*683858#!ecNumber*3.4.22.34#specificActivity*-999#specificActivityMaximum*#commentary*HEK-293-overexpressing legumain cells cleave 100% of the prodrug carbobenzyloxy-Ala-Ala-Asn-ethylenediamine-etoposide, whereas HEK-293 cells, which express low levels of legumain, cleave only 33% of it; HEK-293 serum-starved cells show a slight 1.2fold increase in enzymatic activity toward carbobenzyloxy-Ala-Ala-Asn-amido-4-methyl coumarin compared to that of nonstarved 293 HEK cells, while PC-3 serum-starved or nonstarved cells shows no significant difference in enzymatic activity#organism*Homo sapiens#literature*696499#!ecNumber*3.4.22.34#specificActivity*-999#specificActivityMaximum*#commentary*the specific activity of recombinant asparaginyl endopeptidase is lower than that detected for excretory-secretory products of adult worm#organism*Opisthorchis viverrini#literature*698344#!ecNumber*3.4.22.34#specificActivity*-999#specificActivityMaximum*#commentary*asparaginyl endopeptidase deficiency provokes extramedullary hematopoiesis in the spleen and abnormally enlarged histiocytes with ingested red blood cells in bone marrow; asparaginyl endopeptidase depletion evidently enhances the phagocytic activity, suggesting that phagocytic activity of macrophages in asparaginyl endopeptidase-/- mice is elevated; disruption of asparaginyl endopeptidase leads to late endosomes and lysosomes augmentation and dislocation from the apical region of the kidney-proximal tubule cells and the abnormal lysosomes contained in electron-dense or membranous materials; in contrast to the enhanced macrophage activity, the natural killer cell activity in the asparaginyl endopeptidase-null animal is significantly reduced; mutant mice lacking asparaginyl endopeptidase develop fever, cytopenia, hepatosplenomegaly and hemophagocytosis, which are primary pathological manifestations of hemophagocytic syndrome/hemophagocytic lymphohistiocytosis; myeloid cells are also increased in the asparaginyl endopeptidase-null mice, e.g. 10.2% in asparaginyl endopeptidase-null mice versus 1.2% in wild-type; red blood cells from asparaginyl endopeptidase-null mice are defective in plasma membrane components; the liver is significantly enlarged in asparaginyl endopeptidase deficient mice as compared with the normal counterparts; the percentage of Ter-119+/CD45+ erythroid lineage cells in the spleen is increased in the asparaginyl endopeptidase-deficient mice, e.g. 18.2% in a representative asparaginyl endopeptidase-null mouse compared with just 0.4% in a wild type control; the processing of the lysosomal proteases cathepsins in kidney is completely defective in asparaginyl endopeptidase-deficient mice with accumulation of macromolecules in the lysosomes, which is typically seen in lysosomal disorders; the spleens from asparaginyl endopeptidase-null mice are 5-10times larger than those of wild type controls#organism*Mus musculus#literature*701007#!ecNumber*3.4.22.34#specificActivity*0.000133#specificActivityMaximum*#commentary*hydrolysis of substrate benzyloxycarbonyl-Ala-Ala-Asn-4-methyl-coumaryl-7-amide#organism*Haemaphysalis longicornis#literature*699391#!ecNumber*3.4.22.34#specificActivity*0.00041#specificActivityMaximum*#commentary*hydrolysis of substrate acetyl-aspartyl-asparaginyl-leucyl-aspartic acid alpha-(4-methylcoumaryl-7-amide)#organism*Haemaphysalis longicornis#literature*699391#!ecNumber*3.4.22.34#specificActivity*0.642#specificActivityMaximum*#commentary*recombinant protein, 37&Acirc;&deg;C, pH 7, benzyloxycarbonyl-Ala-Ala-Asn-4-methylcoumarin-7-amide, activity profile shown, inhibition assay described, up-regulation by the host blood-feeding process shown by in vitro proteolysis assay#organism*Haemaphysalis longicornis#literature*683541#!ecNumber*3.4.22.34#specificActivity*1.35#specificActivityMaximum*#commentary*membrane-bound fraction#organism*Haemonchus contortus#literature*670470#!ecNumber*3.4.22.34#specificActivity*1.53#specificActivityMaximum*#commentary*purified enzyme#organism*Bos taurus#literature*650376#!ecNumber*3.4.22.34#specificActivity*4.5#specificActivityMaximum*#commentary*purified enzyme#organism*Phaseolus vulgaris#literature*650457#!ecNumber*3.4.22.34#specificActivity*7#specificActivityMaximum*#commentary*purified enzyme#organism*Sus scrofa#literature*649664#!ecNumber*3.4.22.34#specificActivity*7#specificActivityMaximum*#commentary*purified enzyme#organism*Sus scrofa#literature*650457#!ecNumber*3.4.22.34#specificActivity*7.04#specificActivityMaximum*#commentary*purified enzyme, substrate casein#organism*Phaseolus vulgaris#literature*651047#!ecNumber*3.4.22.34#specificActivity*8.1#specificActivityMaximum*#commentary*purified enzyme, substrate benzyloxycarbonyl-Ala-Ala-Asn-4-methylcoumarin-7-amide, pH 5.8, 30&Acirc;&deg;C#organism*Sus scrofa#literature*651877#